Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
N Shorts
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectationsBusiness live – latest updatesThe owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials.Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish firm’s CagriSema drug fell short of investors’ expectations. Continue reading…
Technically enhanced content presented under fair use in public-interest journalism.
